TEMPOL inhibits SARS-CoV-2 replication and development of lung disease in the Syrian hamster model

. 2022 Sep 6;25(10):105074. doi: 10.1016/j.isci.2022.105074

Group	N	Treatment (SQ)	Dose	TX Days	SD 0 - Challenge (IN)	Tissue Collection
1	8 (4M/4F)	Vehicle control	1.5 mL	2 HR pre-Challenge, BID on SD 1-3, SID on SD 4-9	SD 0: SARS-CoV-2	2/grp/sex on SD 4, 10: left lung in 10% NBF for histology
2	8 (4M/4F)	TEMPOL	50 mg/kg in 1.5 mL	2 HR pre-Challenge, BID on SD 1-3, SID on SD 4-9	SD 0: SARS-CoV-2	2/grp/sex on SD 4, 10: left lung in 10% NBF for histology

∗NBF, neutral buffered formalin; M, male; F, female; HR, hour; SQ, subcutaneous; TX, treatment.

At necropsy, lung was collected and placed in 10% neutral buffered formalin for histopathologic analysis. Fixed tissues were processed to hematoxylin and eosin-stained slides and examined by a board-certified pathologist at Experimental Pathology Laboratories, Inc. (EPL) in Sterling, Virginia.